Twist Bioscience Co. (NASDAQ:TWST) Receives $51.22 Consensus PT from Analysts

Twist Bioscience Co. (NASDAQ:TWST) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $51.78.

TWST has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Barclays lowered their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird increased their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Finally, Leerink Partners lifted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,057 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the transaction, the senior vice president now owns 121,013 shares in the company, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 over the last ninety days. 3.92% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TWST. Silvercrest Asset Management Group LLC raised its position in Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock valued at $4,605,000 after buying an additional 37,376 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after purchasing an additional 83,287 shares in the last quarter. Magnetar Financial LLC purchased a new position in Twist Bioscience during the first quarter worth about $389,000. Price T Rowe Associates Inc. MD grew its position in Twist Bioscience by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after purchasing an additional 2,292 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $402,000.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $42.23 on Tuesday. The business has a 50 day moving average of $43.78 and a 200-day moving average of $46.10. Twist Bioscience has a 1 year low of $23.07 and a 1 year high of $60.90. The company has a market capitalization of $2.51 billion, a P/E ratio of -11.73 and a beta of 1.78.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.